search
Back to results

Phase III Study Comparing Two Methods of Cardioplegia in Aortic Valve Surgery Custodiol-N Versus Custodiol (Custodiol-AV)

Primary Purpose

Aortic Valve Disease, Coronary Artery Disease (CAD)

Status
Completed
Phase
Phase 3
Locations
Germany
Study Type
Interventional
Intervention
Custodiol-N
Custodiol
Sponsored by
Dr. F. Köhler Chemie GmbH
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Aortic Valve Disease focused on measuring aortic valve disease, coronary bypass surgery, cardioplegic solutions

Eligibility Criteria

30 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients >/= 30 and </= 85 years of age
  • Male or female with aortic valve disease
  • Able to understand character and individual consequences of the clinical trial and to provide written informed consent to participate in the study
  • Women of childbearing potential (ie, those who have not undergone a hysterectomy or who have not been post-menopausal for at least 12 consecutive months) must test negative for pregnancy prior to bypass surgery.

Exclusion Criteria:

  • History of recent (< 6 weeks) Q-wave myocardial infarction
  • Left ventricular ejection fraction < 25% (as assessed by any one of the following: contrast ventriculography, multigated acquisition scanning [MUGA], or 2-D ECHO)
  • Patients on intra-aortic balloon devices or with history of previous coronary artery bypass surgery
  • Pregnant or lactating patients
  • Patients who have participated in any other investigational studies within 30 days previous to enrollment
  • Patients in cardiogenic shock (defined as a systolic BP < 90 mmHg for over one hour despite inotropic and chronotropic support)
  • Patients with severe chronic obstructive lung disease (FEV1 < 50%)
  • Previous cardiac valvular disease (clinical relevant)
  • GFR <60 ml/min
  • Planned Ross-procedure, Mitral valve surgery, Aortic valve reconstruction, double valve surgery, other concomitant operations excluding coronary artery bypass surgery or closing a patent foramen ovale
  • Evidence of severe organic (e.g. cirrhosis of the liver) or psychiatric disease by history or physical examination
  • History of alcohol abuse, illicit drug use, significant mental illness, physical dependence to any opioid, or any history of drug abuse or addiction within 12 months of study enrollment.

Sites / Locations

  • Klinik für Herzchirurgie, Universitätsklinikum Heidelberg
  • Klinik für Herz- und Gefäßchirurgie GmbH, Herz-Kreislauf-Zentrum Rotenburg
  • Klinik für Herzchirurgie Universität Leipzig/ Herzzentrum Leipzig
  • Klinik für Herz- und Thoraxchirurgie Universitätsklinikum Jena
  • Klinik für Thorax-, Herz- und Gefäßchirurgie, Uniklinik der RWTH Aachen
  • Klinik für Gefäßchirurgie, Universitäres Herzzentrum am UKE Hamburg

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Custodiol-N

Custodiol

Arm Description

comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery

comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery

Outcomes

Primary Outcome Measures

peak value for CK-MB

Secondary Outcome Measures

Catecholamine requirement on SICU

Full Information

First Posted
February 14, 2014
Last Updated
January 14, 2020
Sponsor
Dr. F. Köhler Chemie GmbH
search

1. Study Identification

Unique Protocol Identification Number
NCT02098772
Brief Title
Phase III Study Comparing Two Methods of Cardioplegia in Aortic Valve Surgery Custodiol-N Versus Custodiol
Acronym
Custodiol-AV
Official Title
A Prospective Randomized Double Blind Multicenter Phase III Study Comparing Two Methods of Cardioplegia in Aortic Valve Surgery Custodiol-N Versus Custodiol
Study Type
Interventional

2. Study Status

Record Verification Date
February 2018
Overall Recruitment Status
Completed
Study Start Date
May 2014 (Actual)
Primary Completion Date
November 16, 2018 (Actual)
Study Completion Date
December 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Dr. F. Köhler Chemie GmbH

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The objective of this investigation is to compare the cardioprotective effects and safety of two cardioplegic solutions, HTK Cardioplegic Solution (Custodiol) and Custodiol-N in patients undergoing aortic valve surgery. The study design is a prospective, double blind, multicenter, randomized, Phase III comparison study intended to demonstrate superiority in surgical outcome between Custodiol and Custodiol-N as determined by CK-MB peak value 4-24 hours after opening of the aortic cross-clamp (primary endpoint), catecholamine requirement (cumulative dose) and cardiac Troponin T, occurrence of comorbid events postoperatively (e.g., myocardial infarction).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Aortic Valve Disease, Coronary Artery Disease (CAD)
Keywords
aortic valve disease, coronary bypass surgery, cardioplegic solutions

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Factorial Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
530 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Custodiol-N
Arm Type
Experimental
Arm Description
comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
Arm Title
Custodiol
Arm Type
Active Comparator
Arm Description
comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
Intervention Type
Drug
Intervention Name(s)
Custodiol-N
Intervention Description
comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
Intervention Type
Drug
Intervention Name(s)
Custodiol
Intervention Description
comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
Primary Outcome Measure Information:
Title
peak value for CK-MB
Time Frame
measured at 4, 8, 12, 16, 20 and 24 hours after the release of the aortic cross clamp
Secondary Outcome Measure Information:
Title
Catecholamine requirement on SICU
Time Frame
within 24 hours (cumulative dose)
Other Pre-specified Outcome Measures:
Title
Safety parameters
Description
documentation and reporting of AE and SAE
Time Frame
from time of the study inclusion up to the follow-up visit on day 5

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients >/= 30 and </= 85 years of age Male or female with aortic valve disease Able to understand character and individual consequences of the clinical trial and to provide written informed consent to participate in the study Women of childbearing potential (ie, those who have not undergone a hysterectomy or who have not been post-menopausal for at least 12 consecutive months) must test negative for pregnancy prior to bypass surgery. Exclusion Criteria: History of recent (< 6 weeks) Q-wave myocardial infarction Left ventricular ejection fraction < 25% (as assessed by any one of the following: contrast ventriculography, multigated acquisition scanning [MUGA], or 2-D ECHO) Patients on intra-aortic balloon devices or with history of previous coronary artery bypass surgery Pregnant or lactating patients Patients who have participated in any other investigational studies within 30 days previous to enrollment Patients in cardiogenic shock (defined as a systolic BP < 90 mmHg for over one hour despite inotropic and chronotropic support) Patients with severe chronic obstructive lung disease (FEV1 < 50%) Previous cardiac valvular disease (clinical relevant) GFR <60 ml/min Planned Ross-procedure, Mitral valve surgery, Aortic valve reconstruction, double valve surgery, other concomitant operations excluding coronary artery bypass surgery or closing a patent foramen ovale Evidence of severe organic (e.g. cirrhosis of the liver) or psychiatric disease by history or physical examination History of alcohol abuse, illicit drug use, significant mental illness, physical dependence to any opioid, or any history of drug abuse or addiction within 12 months of study enrollment.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gabor Szabó, Prof.
Organizational Affiliation
Department of Cardiac Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg
Official's Role
Principal Investigator
Facility Information:
Facility Name
Klinik für Herzchirurgie, Universitätsklinikum Heidelberg
City
Heidelberg
State/Province
Baden-Württemberg
ZIP/Postal Code
69120
Country
Germany
Facility Name
Klinik für Herz- und Gefäßchirurgie GmbH, Herz-Kreislauf-Zentrum Rotenburg
City
Rotenburg an der Fulda
State/Province
Hessen
ZIP/Postal Code
36199
Country
Germany
Facility Name
Klinik für Herzchirurgie Universität Leipzig/ Herzzentrum Leipzig
City
Leipzig
State/Province
Sachsen
ZIP/Postal Code
04289
Country
Germany
Facility Name
Klinik für Herz- und Thoraxchirurgie Universitätsklinikum Jena
City
Jena
State/Province
Thüringen
ZIP/Postal Code
07747
Country
Germany
Facility Name
Klinik für Thorax-, Herz- und Gefäßchirurgie, Uniklinik der RWTH Aachen
City
Aachen
ZIP/Postal Code
52074
Country
Germany
Facility Name
Klinik für Gefäßchirurgie, Universitäres Herzzentrum am UKE Hamburg
City
Hamburg
ZIP/Postal Code
20246
Country
Germany

12. IPD Sharing Statement

Learn more about this trial

Phase III Study Comparing Two Methods of Cardioplegia in Aortic Valve Surgery Custodiol-N Versus Custodiol

We'll reach out to this number within 24 hrs